Depomed (DEPO): Raising PT to $27 - Mizuho

September 19, 2016 9:23 AM EDT
Get Alerts DEPO Hot Sheet
Price: $23.21 -0.21%

Rating Summary:
    10 Buy, 5 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 17 | Down: 27 | New: 7
Trade DEPO Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Mizuho Securities analyst, Irina Koffler, reiterated her Buy rating on shares of DepoMed Inc (NASDAQ: DEPO) and raised her price target to $27 from $23 after extending her model to 2024 to incorporate a longer-term view of the business. The analyst believes a 2024-2025 settlement for Nucynta/ ER would allow her to model the patent cliffs for the remainder of DEPO's portfolio.

A takeout seems more likely however. Horizon acquired RPTP for 6.6x LTM Procysbi sales but the analyst thinks that DEPO's lower margin pain drugs could go for a lower 5x sales multiple. If she applies a multiple of 5x to a 2017 estimate of $545M, and subtracts net debt of $346M, the analyst arrives at a takeout per share value of $29.

For an analyst ratings summary and ratings history on DepoMed Inc click here. For more ratings news on DepoMed Inc click here.

Shares of DepoMed Inc closed at $24.34 yesterday

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Irina Koffler

Add Your Comment